Juan Andres - 30 Nov 2022 Form 4 Insider Report for Moderna, Inc. (MRNA)

Role: Chief Technical Operations and Quality Officer
Signature: /s/ Brian Sandstrom, as Attorney-in-Fact
Issuer symbol: MRNA
Transactions as of: 30 Nov 2022
Transactions value $: -$305,180
Form type: 4
Filing time: 02 Dec 2022, 15:12:09 UTC
Previous filing: 30 Nov 2022
Next filing: 09 Dec 2022
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	MRNA	Common Stock	Options Exercise	$41.9K	+2K	+15.62%	$20.93^*	14.8K	30 Nov 2022	Direct	F1
transaction	MRNA	Common Stock	Sale	-$347K	-2K	-13.51%	$173.52	12.8K	30 Nov 2022	Direct	F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	MRNA	Stock Option (Right to Buy)	Options Exercise	$0	-2K	-0.94%	$0.00	211K	30 Nov 2022	Common Stock	2K	$20.93	Direct	F1, F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on November 19, 2021.
F2	25% of this option vested and became exercisable on March 8, 2020 with the remainder vesting in twelve (12) equal quarterly installments thereafter.

Remarks:

Chief Technical Operations and Quality Officer